Search alternatives:
26 decrease » 026 decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
26 decrease » 026 decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
-
1
-
2
-
3
-
4
Mutations in <i>rbm-26</i> cause axon degeneration and axon overlap defects.
Published 2024Subjects: -
5
Third.
Published 2024“…It revealed that the total systematic spillover exhibited an initial increase, followed by a subsequent decrease. Notably, the fluctuation in this phenomenon intensified significantly during the epidemic. …”
-
6
Histogram of number of drugs with (a) increased and (b) decreased usage within 12 months.
Published 2024“…<p>There are 162 out of 237 PWUDs with an increase and 188 with a decrease in usage of at least one drug.</p>…”
-
7
-
8
-
9
-
10
-
11
Repetitive stress induces a decrease in sound-evoked activity.
Published 2025“…Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 185.6, <i>p</i> = 4.8 × 10<sup>−42</sup>, condition: intensity interaction F = 10.37, <i>p</i> = 9.3 × 10<sup>−21</sup>, nested ANOVA (mouse nested within session), condition F = 174, <i>p</i> = 1.5 × 10<sup>−39</sup>, condition: intensity interaction F = 12.7, <i>p</i> = 2 × 10<sup>−26</sup>, post hoc for each level baseline versus repetitive stress <i>p</i> < 0.01 for all levels above 50 dB, all Bonferroni corrected). …”
-
12
-
13
-
14
Annual treatment frequencies in recurrence and non-recurrence groups.
Published 2025“…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”
-
15
Annual number of outpatient visits in all eyes.
Published 2025“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
16
Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups.
Published 2025“…These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”
-
17
Annual treatment frequencies in all eyes.
Published 2025“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
-
18
BrdU incorporation is elevated in clrn1-/- zebrafish at 4 mpf and decreases with age.
Published 2025“…<p>Anti-BrdU (green) staining in paraffin sections from (a,a’) 4 mpf, (b,b’) 8 mpf, (c,c’) 12 mpf, and (d,d’) 20 mpf in wild-type and <i>clrn1</i><sup><i>-/-</i></sup> zebrafish retinas. …”
-
19
-
20
Histograms of the extent of the (a) increase and (b) decrease by the difference in categorical usage within 12 months for all drugs.
Published 2024“…<p>Histograms of the extent of the (a) increase and (b) decrease by the difference in categorical usage within 12 months for all drugs.…”